Chemocentryx, Inc.

Amgen Inc.

Howard S Roth

Penglie Zhang

Rajinder Paul Singh

Sreenivas Punna

Viengkham Malathong

Darren J McMurtrie

Ju Yang

Jeffrey P McMahon

Venkat Reddy Mali

Christopher W Lange

Yu Wang

Rebecca M Lui

Daniel R Marshall

Aubrie Harland

Yibin Zeng

Pingchen Fan

Antoni Krasinski

Kwok Yau

Jeffrey Mcmahon

Darren J Mcmurtrie

Rajinder Singh

Compounds of formula (A) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:

Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors

Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:

Aryl sulfonyl compounds as CCR6 inhibitors

Compounds represented by Formula (I) or (II): are provided herein, or a pharmaceutically acceptable salt, or a prodrug or bioisostere thereof; wherein R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, Y, Y′, and the subscripts m and n are as defined herein.

Indanes as PD-L1 inhibitors

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R, R, R, R, R, R, R, R, R, R, R, R, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Immunomodulator compounds

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II):

Macrocyclic immunomodulators

Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, R, R, R, R, Rand the subscript n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Compounds for treatment of PD-L1 diseases

Provided herein are salt forms of a complement component 5a receptor having the formula of Compound 1  Also provided herein are pharmaceutical compositions and methods of treatment using the salt forms of Compound 1, described herein.

Salt forms of a complement component C5A receptor

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II): 

Growing community of inventors

Sunnyvale, CA, United States of America

Howard S Roth